Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Warm thoughts and prayers will be with you through your surgery and wishes are sent for speedy recovery.
Message sent
First Word Pharma actually picked up the PR from NWBO regarding the $5 million loan and posted it twice - under “Latest News” and “Story Watch.” I am stunned…is the drought over?
https://www.firstwordpharma.com
Cognate Announces the Appointment of Two Independent Board Members
https://www.cognatebioservices.com/insights/cognate-announces-the-appointment-of-two-independent-board-members
Merck to build £1B London R&D hub for its first ex-U.S. early research center
https://www.fiercebiotech.com/biotech/merck-to-build-ps1-billion-london-r-d-hub-for-its-first-ex-u-s-early-research-center
Of interest:
Sanofi enters $3.7-billion deal to buy Principia Biopharma
https://www.firstwordpharma.com/node/1749635?tsid=28
Pumpernickel....
Very sorry for your sadness. Prayers and good thoughts on their way to you.
Cognate has launched new website:
https://www.cognatebioservices.com
Of interest.....
INmune Bio, Inc. Featured on Fox News (VIDEO): STNF and Cytokine Storm
LA JOLLA, Calif, July 27, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease was featured on a Fox Business News segment.
Fox Business News reports: “INmune Bio CEO, President and acting CMO Dr. Raymond Tesi, M.D. talks about INmune Bio's proposed phase two human trials of possible treatment of coronavirus patients using an anti-inflammatory drug and addresses the effort for lower drug costs.”
To watch the full interview, please visit the link below: https://video.foxbusiness.com/v/6174850319001/?playlist_id=937116503001#sp=show-clips
Recently Noted - Sr. Staff addition to Cognate’s leadership team:
Ron Branning - Global Head of Quality
Cognate BioServices
https://www.cognatebioservices.com/leadership/
Interesting: (apologies if this is a duplicate posting)
Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA (pembrolizumab) in Non-Small Cell Lung Cancer
https://www.firstwordpharma.com/node/1740704?tsid=28®ion_id=4
Absolutely! I knew you would catch that one.
The U.S. Food and Drug Administration today launched Project Patient Voice, an initiative of the FDA's Oncology Center of Excellence (OCE). Through a new website, Project Patient Voice creates a consistent source of publicly available information describing patient-reported symptoms from cancer trials for marketed treatments. While this patient-reported data has historically been analyzed by the FDA during the drug approval process, it is rarely included in product labeling and, therefore, is largely inaccessible to the public.
https://www.firstwordpharma.com/node/1735114?tsid=28®ion_id=2
Appreciate your added info, LF95...
Of interest:
Cobra Biologics signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate
Providing large scale manufacturing capacity for AZD1222
KEELE, United Kingdom, June 16, 2020 /PRNewswire/ — Cobra Biologics (Cobra), part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, today announced it has signed a supply agreement with AstraZeneca UK Ltd. (“AstraZeneca”) to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19. The production agreement is part of AstraZeneca’s recently announced in-licensed programme with the University of Oxford to ensure broad and equitable supply of the vaccine throughout the world, at no profit during the COVID-19 pandemic.
https://www.cognatebioservices.com/cobra-biologics-signs-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine-candidate/
Of interest: link to join the presentation in body of INMB’s PR:
INmune Bio, Inc. to Speak on COVID-19 Therapeutic Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020
“Inflammation is a key element to the pathology seen in patients with COVID-19. Any treatment that targets the complications of COVID-19 should somehow explain why hypertension and obesity are such important risk factors to hospitalization from this vexing disease,” said RJ Tesi. “We believe endothelial activation caused by soluble TNF is an unrecognized driver of the disease. Patients with hypertension and obesity already have inflamed endothelial cells. With the added stimulus of the cytokine storm, the response is dramatic. We believe targeting sTNF is the ideal anti-cytokine therapy for treating the complications of COVID-19 as it targets inflammation without immunosuppressing the host.”
https://www.inmunebio.com/index.php/en/news-2/2020/324-muneionctopeakon19herapeuticanelat20200428
White House denies rumours that HHS Secretary Alex Azar will be replaced over handling of response to COVID-19 pandemic
https://www.firstwordpharma.com/node/1718631?tsid=28®ion_id=6
Advent Bio recently brought aboard a Facilities Manager
https://www.adventbio.uk/our-team
Of interest:
INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19
https://www.inmunebio.com/index.php/en/news-2/2020/321-muneioncnnouncesnitiationoflinicalrogram20200420
Article in First Word Pharma this morning:
https://www.firstwordpharma.com/node/1716718?tsid=28®ion_id=4
Senti
Your post of added-value is most appreciated. I believe NWBO management is very careful to select verbiage that will convey subtle messages and LP’s statements today were well received by those who wish them well.
Thank you Ike….much easier to highlight the presentation with the peppering of the word “excited.” I think it is very meaningful.
“We are excited by the progress that we’ve been making in finalizing the data and moving toward data lock, unblinding, and topline data.”
“….we’re proud of the progress and excited about the progress that we had already made…”
“I can assure you, management and the board are every bit as anxious and excited to get to the stage of unblinding and see those results…”
“….but we think the finish line is in sight now and we’re excited to be able to lay out this guidance for you…”
“And that’s basically what we wanted to convey and we hope that everyone’s as excited as we are.”
Additional info:
“The University of Oxford’s The Jenner Institute has agreed to produce the vaccine with an Italian manufacturer called Advent Srl to initially produce the first batch of the novel coronavirus vaccine for clinical testing back in February. According to a University of Oxford news release then, the vaccine ‘seed stock’ is produced at the University’s Clinical Biomanufacturing Facility and would be transferred to Advent who planned on producing 1,00 doses for the fist clinical trials of the vaccine known as ChAdOx1 nCoV-19.”
https://www.trialsitenews.com/university-of-oxford-commences-clinical-trial-for-vaccine-candidate-chadox1-ncov-19-targeting-covid-19-2/
https://www.irbm.com/news/the-jenner-institute-signs-an-agreement-with-advent-to-develop-a-novel-coronavirus-vaccine/
Longfellow95
Thanks for offering the board details on Cobra Biologics/Jenner Institute
Of interest:
“Cobra Biologics is proud to be part of a consortium to rapidly develop a COVID-19 vaccine” (Cognate BioServices completed the acquisition of Cobra Biologics Jan 2020)
https://www.cobrabio.com/News
Take care of YOU
Truthfan
6, 9, 11, 17, 21
Thanks Ike, Senti, et al.
Perhaps Duffy’s assignment was to hammer out an MOU with LP and LG as a prelude to a contract. His presence at NWBO had to be as an employee.
So sorry for your loss Captain O. My deepest sympathies.